62019-56-1 Usage
General Description
2,4-dichloro-5-thiazolecarboxylic acid is a chemical compound that belongs to the class of organic compounds known as thiazolecarboxylic acids and derivatives. Thiazoles are compounds containing a five-member aromatic ring made up of one sulfur atom, one nitrogen atom, and three carbon atoms while carboxylic acids have a -COOH group. The presence of two chlorine atoms contributes to the unique properties of this chemical. It is also known as SCHEMBL2318647, and the molecular formula is C4HCl2NO2S. It has potential applications in various chemical and pharmaceutical industries. Due to its potential hazardous effects, its handling requires proper safety precautions.
Check Digit Verification of cas no
The CAS Registry Mumber 62019-56-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,0,1 and 9 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 62019-56:
(7*6)+(6*2)+(5*0)+(4*1)+(3*9)+(2*5)+(1*6)=101
101 % 10 = 1
So 62019-56-1 is a valid CAS Registry Number.
InChI:InChI=1/C4HCl2NO2S/c5-2-1(3(8)9)10-4(6)7-2/h(H,8,9)
62019-56-1Relevant articles and documents
COMPOUNDS, COMPOSITIONS, AND METHODS
-
Paragraph 0182; 0214, (2017/09/27)
The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
Novel insecticides
-
Page/Page column 23-24, (2013/02/27)
Compounds of formula I wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.
Novel chemical compounds
-
Page/Page column 8, (2009/10/31)
This invention relates to newly identified compounds for inhibiting hYAK3 and/or CK2 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 and/or CK2 proteins.
